In recent years, SATB2 has gained increasing attention as a relatively specific marker of colorectal differentiation [23,24,25,26] and functional studies have revealed the tumour-suppressive properties of SATB2 in experimental settings [12,27,28,29,30], demonstrating that SATB2 is a complexly regulated tumour suppressor that represses CRC progression by inhibiting the transcription of SNAIL, a master regulator of epithelial-mesenchymal transition. The gene discussed is SNAI1; the disease is neoplasm.